These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity
These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity
Trey Thoelcke Thu, March 19, 2026 at 1:10 PM UTC
0
monsitj / iStock via Getty Images (monsitj / iStock via Getty Images)Quick Read -
Bristol Myers Squibb (BMY) reported Q4 2025 non-GAAP EPS of $1.26, missing consensus by 22.7% due to a $1.39B acquired IPRD charge, while legacy drugs Revlimid and Sprycel fell 55% and 60% respectively with generic pomalidomide entry expected in Q1 2026. FedEx (FDX) beat Q2 FY2026 adjusted EPS estimates by over 17% at $4.82 with a planned Freight spin-off targeted for June 1, 2026, and raised full-year guidance to $17.80-$19.00 adjusted EPS. Ralph Lauren (RL) delivered Q4 revenue of $2.406B beating estimates by 4.16% with EPS of $6.22 topping expectations by 7.10%, plus 22.4% Asia revenue growth with China up over 30% for the second straight quarter.
A death cross technical signal has formed for all three stocks, but Bristol Myers Squibb faces genuine fundamental headwinds from legacy drug obsolescence and pipeline binary risks, while FedEx and Ralph Lauren show strong recent earnings beats and positive guidance despite the technical breakdown reflecting broader market volatility rather than company-specific deterioration.
A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here.
A death cross forms when a stock's 50-day moving average crosses below its 200-day moving average, signaling a potential downtrend. Right now, Bristol Myers Squibb (NYSE: BMY), FedEx (NYSE: FDX), and Ralph Lauren (NYSE: RL) are all flashing that signal. With the CBOE Volatility Index (VIX) at around 25, elevated macro uncertainty is clustering these technical breakdowns across sectors. But the signal does not carry equal weight for all three. Here is how they rank, from most technically justified to least technically justified.
3. Bristol Myers Squibb: The Death Cross With the Most Fundamental Support
Bristol Myers Squibb, or BMS, presents the weakest fundamental case for ignoring the bearish signal. The stock is up 10% year-to-date and trades around $59.30, but the forward picture is discouraging. An AI price model projects $55.60 with a Hold recommendation, implying roughly 6.4% downside from current levels. Analyst consensus is modestly more optimistic at $62.72, but even that leaves limited upside relative to the risks.
The most recent quarter told a complicated story. Q4 2025 non-GAAP EPS came in at $1.26, missing the $1.63 consensus by 22.7%, largely driven by a $1.39 billion acquired IPRD charge tied to the Orbital Therapeutics acquisition. Revenue of $12.5 billion beat estimates slightly, but full-year 2025 revenue declined 0.22% year-over-year. Legacy drugs are in freefall: Revlimid fell 55% and Sprycel by 60% in Q4, with generic pomalidomide entry expected in Q1 2026. Management's 2026 revenue guidance of $46.0 billion to $47.5 billion implies a step down from 2025 actuals. The pipeline is genuinely rich, with FDA priority review decisions for iberdomide expected by August 2026 and Opdivo in Hodgkin Lymphoma due April 8, 2026, but binary catalysts add risk, not certainty. The death cross here reflects a company in a real transitional squeeze.
Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement
Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.
2. FedEx: A Death Cross With a Silver Lining
FedEx has pulled back roughly 8% over the past month and is down 3.2% over the past week, but zoom out and the picture looks different. The stock is up 42.3% over the past year. That kind of trend does not reverse because of a moving average crossover, and the fundamentals back that up.
Q2 FY2026 adjusted EPS of $4.82 beat estimates by over 17%, and revenue of $23.469 billion beat by 2.94%. Management raised full-year guidance, now projecting adjusted EPS of $17.80 to $19.00. The DRIVE efficiency program is delivering real margin improvement, with adjusted operating margin expanding to 6.9% from 6.3%. A planned spin-off of FedEx Freight, targeted for June 1, 2026, is a structural catalyst not yet fully priced in. Prediction markets currently assign a 94.3% probability that FedEx beats its next quarterly earnings. The AI price model targets $384.05 with a Buy rating, representing roughly 9.8% upside from current levels. The real risk is macro: tariff headwinds on China-U.S. shipments represent a meaningful drag this fiscal year. But the death cross coincides with a broader market pullback rather than an apparent deterioration in company-specific fundamentals.
Advertisement
1. Ralph Lauren: The Strongest Fundamental Case
Ralph Lauren tops this list because no other stock in this group combines consistent execution, margin expansion, and long-term price appreciation that provides context for evaluating the death cross signal. The stock is up 55.4% over the past year and 178.9% over five years. A death cross on a chart like that warrants careful analysis.
The most recent quarter delivered revenue of $2.406 billion, beating estimates by 4.16%, with EPS of $6.22 topping expectations by 7.10%. Revenue grew 12.25% year-over-year, operating margin expanded 220 basis points to 20.9%, and Asia revenue surged 22.4% with China up more than 30% for the second consecutive quarter. Management raised full-year guidance to high-single to low-double digit constant currency revenue growth. The AI price model targets $391.49 with a Buy rating, implying roughly 14.6% upside from current levels, the largest projected gain of the three.
One caution: CEO Patrice Louvet sold nearly 47,000 shares on February 10, 2026, at prices ranging from $347 to $362, and Q4 operating margin is expected to contract 80 to 120 basis points due to tariffs and higher marketing spend. These are real near-term pressures, but they exist within a brand that has compounded shareholder value for years and continues gaining share in premium markets globally.
The Bottom Line
Not all death crosses are created equal. For BMS, the technical signal and fundamentals point in the same direction, with the forward valuation reflecting the company's transitional challenges. For FedEx and Ralph Lauren, the death cross appears to reflect broader market anxiety more than company-specific deterioration. Both carry real risks around tariffs and global trade, but both show analyst price targets above current trading levels, reflecting differing views on the death cross signal's significance.
Data Shows One Habit Doubles American’s Savings And Boosts Retirement
Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.
And no, it’s got nothing to do with increasing your income, savings, clipping coupons, or even cutting back on your lifestyle. It’s much more straightforward (and powerful) than any of that. Frankly, it’s shocking more people don’t adopt the habit given how easy it is.
Source: “AOL Money”
